Lymphokines in autoimmunity--a critical review

Area of Science:

• Immunology
• Autoimmunity Research
• Molecular Medicine

Background:

• The precise mechanisms driving autoimmune diseases remain largely unknown.
• Growing evidence suggests lymphokines are involved in both the initiation and effector stages of autoimmunity.
• Key lymphokines implicated include interferons (IFN), tumor necrosis factor (TNF), and interleukins (IL-1, IL-2).

Purpose of the Study:

• To explore the significant role of lymphokines in the pathogenesis of autoimmune diseases.
• To investigate how lymphokines mediate clinical and laboratory manifestations of autoimmunity.
• To examine the potential of lymphokine manipulation for future autoimmune disease therapies.

Main Methods:

• Reviewing evidence from human therapies and animal models of autoimmunity.
• Analyzing the effects of lymphokine administration and blockade.
• Investigating aberrant MHC class II expression and its link to lymphokines like IFN-gamma.
• Examining cytokine roles in immune cell trafficking and T cell subset activity.

Main Results:

• Therapy with IFN or IL-2 can trigger or exacerbate autoimmune syndromes.
• IFN administration in animals can induce or accelerate autoimmune disease; blockade is protective.
• Elevated lymphokine levels correlate with disease activity in animal models and patients.
• Aberrant MHC class II expression, induced by IFN-gamma, is implicated in organ-specific autoimmunity.

Conclusions:

• Lymphokines, particularly those produced locally and interacting, are crucial in autoimmune disease pathogenesis.
• While initiating events are complex, lymphokines are central players.
• Understanding lymphokine roles opens avenues for targeted therapeutic interventions in autoimmunity.